- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
450
0 new
Companies with a Value score of at least 3, ordered by Value score
450 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
AMPH | US$36.50 | 2.2% | -32.3% | US$1.8b | US$56.40 | PE11.1x | E5.8% | n/a | ||
VTRS | US$11.20 | -0.9% | -6.1% | US$13.4b | US$13.45 | PS0.9x | E51.6% | 4.3% | ||
EXAS | US$55.98 | 8.2% | -12.9% | US$10.4b | US$72.19 | PS3.8x | E57.5% | n/a | ||
KNSA | US$20.03 | 8.0% | 9.9% | US$1.4b | US$36.00 | PS3.8x | E46.5% | n/a | ||
COLL | US$32.59 | -2.3% | -1.8% | US$1.1b | US$43.00 | PE11.9x | E26.4% | n/a | ||
IQV | US$204.33 | 3.5% | -5.4% | US$37.1b | US$249.04 | PE26.4x | E13.7% | 0% | ||
ONC | US$222.08 | 5.7% | 37.2% | US$23.7b | US$283.39 | PS7.3x | E64.7% | n/a | ||
ANIP | US$58.64 | 0.3% | 7.3% | US$1.1b | US$78.67 | PS2.1x | E59.0% | n/a | ||
ICLR | US$200.48 | 1.2% | -24.8% | US$16.6b | US$259.88 | PE22.1x | E11.6% | n/a | ||
INDV | US$11.99 | 2.9% | -32.6% | US$1.2b | US$16.50 | PS1.3x | E42.6% | 0% | ||
ACB | US$3.87 | 0.5% | -3.0% | US$305.5m | US$6.08 | PS1x | E129.9% | n/a | ||
FENC | US$6.23 | 12.5% | -37.1% | US$171.1m | US$12.60 | PS3.5x | E48.6% | n/a | ||
FTRE | US$17.78 | 0.5% | -42.5% | US$1.6b | US$22.20 | PS0.5x | E60.7% | n/a | ||
AGIO | US$34.46 | 6.3% | 47.4% | US$2.0b | US$57.00 | PE2.9x | E-29.8% | n/a | ||
AMRX | US$8.68 | 5.1% | 58.1% | US$2.7b | US$10.50 | PS1x | E154.7% | 0% | ||
CRL | US$164.97 | 0.9% | -25.1% | US$8.4b | US$198.40 | PE20.4x | E13.1% | n/a | ||
PTGX | US$37.69 | 2.4% | 51.2% | US$2.2b | US$57.10 | PE13.1x | E0.9% | n/a | ||
ERFS.F | US$51.50 | 4.1% | -15.9% | US$9.1b | US$60.87 | PE27.9x | E18.4% | 1.0% | ||
TCNN.F | US$5.01 | 0.8% | -42.2% | US$1.4b | US$15.27 | PS0.8x | E56.5% | n/a | ||
CURL.F | US$1.31 | -13.2% | -74.4% | US$1.4b | US$4.21 | PS0.7x | E33.9% | n/a | ||
CTKB | US$5.74 | 5.1% | -32.3% | US$739.4m | US$8.38 | PS3.7x | E119.8% | n/a | ||
PCRX | US$24.52 | 9.7% | -23.5% | US$1.1b | US$20.43 | PS1.6x | E53.5% | n/a | ||
EVO | US$4.30 | 4.6% | -45.6% | US$1.4b | US$5.86 | PS1.9x | E65.0% | n/a | ||
RPRX | US$31.06 | 1.0% | 6.7% | US$13.8b | US$40.70 | PE12.1x | E4.3% | 2.8% |